Antisense's Duchenne's muscular dystrophy program has somehow snuck underneath investors noses and looks to be grossly undervalued. Here's what we know:
ATL1102 has achieved successful phase 2 results with a strong efficacy signal that is clinically significant.
- Performance of Upper Limb (PUL) 2.0 scores show a mean improvement of 0.9 points over 24 weeks compared to the typical decrease of 2.2 points / yr seen in a comparable group of non-ambulant patients. (1)
- 3/9 patients stabilised according to their PUL 2.0 score, with another 4/9 showing improvement, and 2/9 having disease progression.
- On ATL1102, Grip strength has increased by a mean value of 0.2kg, and pinch strength has stabilised showing no change. A study in European DMD non ambulant patients show a mean decrease in grip strength of 0.39kg and pinch strength of 0.08kg over a year. (2)
Looking at the overall picture, we see a drug with a well understood mechanism of action that looks to have a clinically meaningful impact on established endpoints (PUL 2.0, Myopinch). Essentially, these endpoints will be the same endpoints used in the registration trial.
At the current enterprise value of sub $20m, the risk-reward calculus is quite compelling. There are currently 3 FDA approved drugs for DMD selling in 2019.
Exondys-51 (2019 revenue of $381m USD)
Translarna (2019 revenue of $190m USD)
Emflaza (2019 revenue of $101m USD)
Essentially these are all $1-3bn drugs - and Antisense's ATL1102 is only one trial away from achieving the same outcomes both medically and from a economic value standpoint.
Now with AEF selling, it looks to be a good time to stock up.
Comments and criticisms welcome!
References:
1. Mayhew, A., Mazzone, E. S., Eagle, M., Duong, T., Ash, M., Decostre, V., ... & Bianco, F. (2013). Development of the Performance of the U pper L imb module for D uchenne muscular dystrophy. Developmental Medicine & Child Neurology, 55(11), 1038-1045.
2. Ricotti, V., Selby, V., Ridout, D., Domingos, J., Decostre, V., Mayhew, A., ... & Jansen, M. (2019). Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study. Neuromuscular Disorders, 29(4), 261-268.
- Forums
- ASX - By Stock
- Thoughts on ATL1102 for DMD
Antisense's Duchenne's muscular dystrophy program has somehow...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
NEWS
Is oil undervalued?
Add PER (ASX) to my watchlist
(20min delay)
|
|||||
Last
7.9¢ |
Change
0.005(6.76%) |
Mkt cap ! $71.22M |
Open | High | Low | Value | Volume |
7.5¢ | 7.9¢ | 7.5¢ | $65.48K | 860.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 254337 | 7.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
7.9¢ | 411992 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 254337 | 0.074 |
2 | 111973 | 0.073 |
2 | 63400 | 0.072 |
2 | 90000 | 0.070 |
1 | 100333 | 0.066 |
Price($) | Vol. | No. |
---|---|---|
0.079 | 411992 | 3 |
0.080 | 243231 | 2 |
0.081 | 100000 | 1 |
0.082 | 75174 | 2 |
0.083 | 110520 | 2 |
Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
Featured News
NEWS
Is oil undervalued?
BOE
Uranium prices on the NYMEX are stable, but ASX uranium stocks are sinking on Friday. The answer lies in Kazakhstan
DVP
Commodity house Trafigura funds Develop Global's copper-zinc Woodlawn play with offtake deal in place
PER (ASX) Chart |